graph EGM comparisons
pembrolizumab alonetitleatezolizumab alonetitleatezolizumab plus carboplatin plus nab-paclitaxeltitleatezolizumab plus bevacizumab plus carboplatin plus paclitaxeltitlecemiplimabtitledurvalumab alonetitledurvalumab plus tremelimumabtitleatezolizumab plus carboplatin plus paclitaxeltitlenivolumab plus ipilimumabtitlepembrolizumab plus SoCtitlenivolumab alonetitleatezolizumab plus pemetrexed and platintitlenivolumab plus ipilimumab plus SoCtitlesintillimab plus SoCtitlepembrolizumab plus ipilimumabtitlenivolumab plus SoCtitleipilimumab plus SoCtitlepembrolizumab and pemetrexed plus platintitlepembrolizumab plus placebotitlenab-paclitaxeltitlecarboplatin plus nab-paclitaxeltitleplacebo plus SoCtitlepemetrexed plus platintitlebevacizumab plus carboplatin and paclitaxeltitleStandard of Care (SoC)titleEMPOWER lung1 (all population), 2021 NCT03088540 mNSCLC - L1 - all population 356/354MYSTIC (D ; all population), 2020 NCT02453282 mNSCLC - L1 - all population 374/372MYSTIC (DT ; all population), 2020 NCT02453282 mNSCLC - L1 - all population 372/372CheckMate 9LA, 2021 NCT03215706 mNSCLC - L1 - all population 361/358ORIENT-11, 2020 NCT03607539 mNSCLC - L1 - all population 266/131CheckMate 227 (NC vs C ; PDL1<1%), 2018 NCT02477826 mNSCLC - L1 - PDL1 negative 177/186IMpower-110 (TC3 or IC3), 2020 NCT02409342 mNSCLC - L1 - PDL1 positive 107/98IMpower-110 (TC2/3 or IC2/3), 2020 NCT02409342 mNSCLC - L1 - PDL1 positive 166/162IMpower-110 (TC1/2/3 or IC1/2/3), 2020 NCT02409342 mNSCLC - L1 - PDL1 positive 277/277EMPOWER lung1 (PDL1>50%), 2021 NCT03088540 mNSCLC - L1 - PDL1 positive 283/280MYSTIC (D ; PDL1>25%), 2020 NCT02453282 mNSCLC - L1 - PDL1 positive 163/162MYSTIC (DT ; PDL1>25%), 2020 NCT02453282 mNSCLC - L1 - PDL1 positive 163/162CheckMate 026 (PDL1>5%), 2016 NCT02041533 mNSCLC - L1 - PDL1 positive 211/212CheckMate 026 (PDL1>1%), 2016 NCT02041533 mNSCLC - L1 - PDL1 positive 271/270CheckMate 227 (NI vs C ; PDL1>1%), 2018 NCT02477826 mNSCLC - L1 - PDL1 positive 396/397KEYNOTE-042 (PDL1>50%), 2019 NCT02220894 mNSCLC - L1 - PDL1 positive 299/300KEYNOTE-042 (PDL1>20%), 2019 NCT02220894 mNSCLC - L1 - PDL1 positive 413/405KEYNOTE-042 (PDL1>1%), 2019 NCT02220894 mNSCLC - L1 - PDL1 positive 637/637KEYNOTE-024 (PDL1>50%), 2016 NCT02142738 mNSCLC - L1 - PDL1 positive 154/151KEYNOTE-598, 2020 NCT03302234 mNSCLC - L1 - PDL1 positive 284/284CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 NCT02477826 mNSCLC - L1 - TMB>10Mb 139/160IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 NCT02366143 non squamous - mNSCLC - L1 - all population 400/400IMpower-130 (all population), 2019 NCT02367781 non squamous - mNSCLC - L1 - all population 483/240IMpower-150 (ACP vs BCP ; all population, EXPLORATORY), 2018 NCT02366143 non squamous - mNSCLC - L1 - all population 402/400IMpower-150 (ABCP vs BPC WT), 2018 NCT02366143 non squamous - mNSCLC - L1 - Wild Type (WT) 356/336IMpower-150 (ABCP vs BPC ; WT-Teff high), 2018 NCT02366143 non squamous - mNSCLC - L1 - Wild Type (WT) 155/129IMpower-130 (WT), 2019 NCT02367781 non squamous - mNSCLC - L1 - Wild Type (WT) 451/228IMpower-132 (WT), 0 NCT02657434 non squamous - mNSCLC - L1 - Wild Type (WT) 292/286KEYNOTE-021, 2016 NCT02039674 non squamous - mNSCLC - L1 - Wild Type (WT) 60/63KEYNOTE-189, 2018 NCT02578680 non squamous - mNSCLC - L1 - Wild Type (WT) 410/206IMpower-131 (ACnP), 2020 NCT02367794 squamous - mNSCLC - L1 - all population 343/340IMpower-131 (ACP) EXPLORATORY, 2020 NCT02367794 squamous - mNSCLC - L1 - all population 338/340CA184-104, 2017 NCT01285609 squamous - mNSCLC - L1 - all population 479/477KEYNOTE-407, 2018 NCT02775435 squamous - mNSCLC - L1 - all population 278/281

Pathology:  mNSCLC - L1 - all population;   mNSCLC - L1 - PDL1 negative;   mNSCLC - L1 - PDL1 positive;   mNSCLC - L1 - TMB>10Mb;   non squamous - mNSCLC - L1 - all population;   non squamous - mNSCLC - L1 - Wild Type (WT);   squamous - mNSCLC - L1 - all population; 

mNSCLC - L1 - all populationmNSCLC - L1 - PDL1 negativemNSCLC - L1 - PDL1 positivemNSCLC - L1 - TMB>10Mbnon squamous - mNSCLC - L1 - all populationnon squamous - mNSCLC - L1 - Wild Type (WT)squamous - mNSCLC - L1 - all population
EMPOWER lung1 (all population), 2021MYSTIC (D ; all population), 2020MYSTIC (DT ; all population), 2020CheckMate 9LA, 2021ORIENT-11, 2020CheckMate 227 (NC vs C ; PDL1<1%), 2018IMpower-110 (TC3 or IC3), 2020IMpower-110 (TC2/3 or IC2/3), 2020IMpower-110 (TC1/2/3 or IC1/2/3), 2020EMPOWER lung1 (PDL1>50%), 2021MYSTIC (D ; PDL1>25%), 2020MYSTIC (DT ; PDL1>25%), 2020CheckMate 026 (PDL1>5%), 2016CheckMate 026 (PDL1>1%), 2016CheckMate 227 (NI vs C ; PDL1>1%), 2018KEYNOTE-042 (PDL1>50%), 2019KEYNOTE-042 (PDL1>20%), 2019KEYNOTE-042 (PDL1>1%), 2019KEYNOTE-024 (PDL1>50%), 2016KEYNOTE-598, 2020CheckMate 227 (NI vs C ; TMB >10 Mb), 2018IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018IMpower-130 (all population), 2019IMpower-150 (ACP vs BCP ; all population, EXPLORATORY), 2018IMpower-150 (ABCP vs BPC WT), 2018IMpower-150 (ABCP vs BPC ; WT-Teff high), 2018IMpower-130 (WT), 2019IMpower-132 (WT), 0KEYNOTE-021, 2016KEYNOTE-189, 2018IMpower-131 (ACnP), 2020IMpower-131 (ACP) EXPLORATORY, 2020CA184-104, 2017KEYNOTE-407, 2018
pembrolizumab alone4T1T1T1T1
atezolizumab alone3T1T1T1
atezolizumab plus carboplatin plus nab-paclitaxel3T1T0T1T1
atezolizumab plus bevacizumab plus carboplatin plus paclitaxel3T1T1T1
cemiplimab2T1T1
durvalumab alone2T1T1
durvalumab plus tremelimumab2T1T1
atezolizumab plus carboplatin plus paclitaxel2T1T1
nivolumab plus ipilimumab2T1T1
pembrolizumab plus SoC2T1T1
nivolumab alone2T1T1
atezolizumab plus pemetrexed and platin1T1
nivolumab plus ipilimumab plus SoC1T1
sintillimab plus SoC1T1
pembrolizumab plus ipilimumab1T1
nivolumab plus SoC1T1
ipilimumab plus SoC1T1
pembrolizumab and pemetrexed plus platin1T1
pembrolizumab plus placebo0T0
nab-paclitaxel0T0
carboplatin plus nab-paclitaxel0T0T0
placebo plus SoC0T0T0T0T0
pemetrexed plus platin0T0T0T0T0T0
bevacizumab plus carboplatin and paclitaxel0T0T0T0T0
Standard of Care (SoC)0T0T0T0T0T0T0T0T0T0T0T0T0T0T0T0T0